Wake Forest University Baptist Medical Center (WFUBMC)
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ard, Jamy D
LEAP, NCT05176626: Long-term Effectiveness of the Antiobesity Medication Phentermine

Active, not recruiting
4
870
US
Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG, Lomaira
Wake Forest University Health Sciences, Johns Hopkins University, Kaiser Permanente, HealthPartners Institute, The University of Texas Health Science Center, Houston, Biomedical Research Institute of New Mexico, WW International Inc, KVK-Tech, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Obesity; Drug, Lifestyle, Healthy
12/26
12/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
WE RISE U01, NCT04922333: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

Recruiting
3
200
US
Risedronate, Actonel, Atelvia, Placebo
Wake Forest University Health Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Bone Loss
04/28
04/28
NCT04994769: The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

Completed
N/A
33
US
Epitomee Capsule, The MODEL IBT Program
Epitomee medical
Overweight and Obesity
12/23
03/24
NCT05348395: Monocyte Priming When Consuming a Western Diet

Completed
N/A
8
US
Experimental diet
Wake Forest University Health Sciences, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Heart Diseases
10/24
10/24
NCT04663061: Diabetes Data-Assisted Remission Trial (DDART)

Completed
N/A
65
US
Medical weight loss, Diabetes education, Continuous glucose monitoring
Wake Forest University Health Sciences, UnitedHealth Group
Type 2 Diabetes, Obesity
11/24
11/24
VITAL-CGM, NCT05935514: Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

Active, not recruiting
N/A
152
US
WW Intervention, Usual Care
Pennington Biomedical Research Center, WW International Inc
Diabetes Mellitus, Type 2 Diabetes, Obesity
11/25
11/25
Packer, Flint Rudd
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25

Download Options